| Cat. No. |
Product Name |
Information |
| PC-Ab1047 |
Fremanezumab
|
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene–related peptide (CGRP), a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab binds to the calcitonin gene-related peptide (CGRP) ligand, inhibiting the function of CGRP at its receptor, and thereby preventing migraine attacks.. |
| PC-Ab1046 |
CC-90002
|
CC-90002 is a humanized IgG4-PE CD47 antibody that inhibits CD47-SIRPα interaction and enabled phagocytosis across a panel of cancer cell lines. CC-90002 is potentially differentiated from other CD47 immunotherapies by its lack of ability to induce hemagglutination of red blood cells or hemolysis in nonclinical studies. CD47 antibodies can synergize with the CD20 antibody rituximab to induce phagocytosis of NHL cells in vitroand to eliminate lymphoma in mouse models. CD47, also known as Integrin |
| PC-Ab1045 |
Sacituzumab
|
Sacituzumab is a human Trop-2 mAB that targets the Trop-2 protein and attaches to it. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.. |
| PC-Ab1044 |
Isatuximab
|
Isatuximab (SAR650984) binds to a CD38 epitope distinct from that targeted by daratumumab, and can be further differentiated from the latter on the basis of several mechanistic differences, including the ability to induce apoptosis of CD38-expressing cells directly. Isatuximab induces antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and complement dependent cytotoxicity.. |
| PC-Ab1043 |
Daratumumab
|
Daratumumab is a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Daratumumab inhibits the growth of CD38 expressing tumor cells and induces apoptosis (cell death) directly through mediated cross linking and by immune mediated tumor cell lysis through complement dependent cytotoxicity, antibody cell mediated cytotoxicity, and antibody dependent cellular phagocytosis.. |
| PC-Ab1042 |
Belantamab
|
B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis superfamily required for plasma cell survival. BMCA is universally detected on patient-derived myeloma cells and has emerged as a selective antigen to be targeted by novel treatments in multiple myeloma. Belantamab mafodotin (belamaf. |
| PC-Ab1041 |
Sutimlimab
|
Sutimlimab (BIVV009, TNT-009) is a humanized mAb that specifically inhibits the complement (CP)-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Sutimlimab potentially reduce RBC lysis, significantly inhibited complement-mediated activation and proliferation of primary human B cells. antagonism suppressed human Ig-induced activation of B cells derived from patients with rheumatoid arthritis.. |
| PC-Ab1040 |
Utomilumab
|
Utomilumab (PF-05082566) is a ligand-blocking antibody, binds 4-1BB between CRDs 3 and 4, a fully human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB (also called CD137), a protein receptor expressed in many cancer-fighting T cells. Utomilumab (PF-05082566) binds specifically to 4-1BB (CD-137), a receptor protein found in many immune cells, such as T-cells (killer T-cells and helper T-cells) and natural killer cells.. |
| PC-Ab1039 |
Selicrelumab
|
Selicrelumab (RO 7009789) is a fully humanized monoclonal IgG2 antibody that binds CD40 with a very high affinity (Kd=0.4 nM). Selicrelumab does not bind the same site as natural CD40L and hence does not block the natural CD40L-CD40 interaction. Selicrelumab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced immune response. Selicrelumab also binds |
| PC-Ab1038 |
Cusatuzumab
|
Cusatuzumab (ARGX-110) is a human αCD70 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity activity, eliminated LSCs in vitro and in xenotransplantation experiments. Cusatuzumab triggers Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.. |
| PC-Ab1037 |
Codrituzumab
|
Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. Codrituzumab binds to glypican-3 (GPC3). Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma (HCC). Codrituzumab triggers FcγRIIIa-mediated (CD16-mediated) antibody-dependent cell cytotoxicity (ADCC) and/or antibody-dependent cell phagocytosis.. |
| PC-Ab1036 |
Margetuximab
|
Margetuximab (MGAH22) is a Fc engineered HER2-directed monoclonal antibody, increases activation of innate and adaptive anti-ERBB2 immune responses, relative to trastuzumab. Margetuximab binds to the same epitope as trastuzumab, but its Fc domain has been modified to enhance binding to activating FcγRIIIA (CD16A) and reduce its affinity for inhibitory FcγRIIB (CD32B) receptors.. |
